Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PUR5700
- Development stage
- Preclinical
- Lead developer
- Pulmatrix
- Modality
- Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Fragment-Derived Small Molecules → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Inhalation
01
Overview
PUR5700 (previously known as RV7031) is a narrow-spectrum kinase inhibitor (NSKI) being developed for the treatment of acute and chronic respiratory diseases. The drug was initially developed by RespiVert and later acquired by Pulmatrix. It is designed to target specific kinases involved in inflammatory pathways relevant to respiratory conditions, aiming to provide therapeutic benefit with reduced off-target effects compared to broad-spectrum kinase inhibitors. As of the latest available information, there are no registered clinical trials or approved products for this compound[1][2][3].
- Other names
- PUR 5700PUR5700PUR-5700RV 7031RV7031RV-7031
02
Targets
PK (Pyruvate kinase)
Beyond the preview
Go deeper on PUR5700.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PUR5700.